Author: HANCHORBIO INC.

Posted Date:

March 25, 2026

HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

HANCHORBIO INC.

March 25, 2026
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

HANCHORBIO INC.

February 13, 2026
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

HANCHORBIO INC.

February 7, 2026
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

HANCHORBIO INC.

January 28, 2026